A pilot study on efficacy of Lactobacillus CD2 lozenges in preventing oral mucositis (OM) by
high-dose chemotherapy with autologous hematopoietic stem cell transplantation. To test
whether the probiotic Lactobacillus brevis CD2 lozenges can reduce the incidence and severity
of high-dose chemotherapy conditioning regimen induced OM in patients undergoing HSCT.
Clinical activity will be defined as reduction in the incidence of chemotherapy induced OM in
the patients undergoing HSCT.